Closer to home: Local care improves compliance with RSV prophylaxis in high-risk infants

Article English OPEN
Singleton, Rosalyn J. ; Bruden, Dana ; Brooks, Lisa ; DeLeon, Jenni ; Vercelline, Anna ; Butler, Jay C. (2012)
  • Publisher: Co-Action Publishing
  • Journal: International Journal of Circumpolar Health (issn: 1797-237X, eissn: 1239-9736)
  • Related identifiers: doi: 10.3402/ijch.v65i1.17886
  • Subject: respiratory syncytial virus, palivizumab, Alaska Native
    mesheuropmc: education | health care economics and organizations | geographic locations

International Journal of Circumpolar Health 65:1 2006Keywords: respiratory syncytial virus, palivizumab, Alaska Native
  • References (7)

    1. Leader S, Kohlhase K. Respiratory syncytial viruscoded pediatric hospitalizations 1997 to 1999. Pediatr Infect Dis J 2002;21:629-32.

    2. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998;102:531-7.

    3. Karron RA, Singleton R, Bulkow L, et al. Severe respiratory syncytial virus disease in Alaska Native children. J Infect Dis 1999;180:41-9.

    4. Singleton R, Dooley L, Bruden D, Raelson S, Butler JC. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J 2003;22(6):540-5.

    5. AAP Committe on Infectious Disease and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998;102:1211-18.

    6. Mullins JA, LaMonte AC, Bresee JS, Anderson LJ. Substantial variability in RSV seasonality in the U.S. Pediatr Infect Dis J 2003;22:857-62.

    7. Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respriatory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004;23:318-22.

  • Metrics
    No metrics available
Share - Bookmark